INBX
Income statement / Annual
Last year (2024), Inhibrx Biosciences, Inc.'s total revenue was $200.00 K,
a decrease of 88.89% from the previous year.
In 2024, Inhibrx Biosciences, Inc.'s net income was $1.69 B.
See Inhibrx Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$200.00 K |
$1.80 M |
$2.18 M |
$7.13 M |
$12.81 M |
$9.09 M |
$7.50 M |
$7.95 M |
$6.67 M |
| Cost of Revenue |
$2.29 M
|
$1.19 M
|
$2.85 M
|
$2.69 M
|
$73.50 M
|
$47.91 M
|
$33.45 M
|
$25.51 M
|
$16.99 M
|
| Gross Profit |
-$2.09 M
|
$609.00 K
|
-$668.00 K
|
$4.44 M
|
-$60.69 M
|
-$38.81 M
|
-$25.95 M
|
-$17.56 M
|
-$10.33 M
|
| Gross Profit Ratio |
-10.43
|
0.34
|
-0.31
|
0.62
|
-4.74
|
-4.27
|
-3.46
|
-2.21
|
-1.55
|
| Research and Development Expenses |
$203.74 M
|
$190.65 M
|
$110.19 M
|
$71.44 M
|
$73.50 M
|
$47.91 M
|
$33.45 M
|
$25.51 M
|
$16.99 M
|
| General & Administrative Expenses |
$127.91 M
|
$29.38 M
|
$21.12 M
|
$12.36 M
|
$6.84 M
|
$9.02 M
|
$4.65 M
|
$2.61 M
|
$1.82 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$253.00 K
|
| Selling, General & Administrative Expenses |
$127.91 M
|
$29.38 M
|
$21.12 M
|
$12.36 M
|
$6.84 M
|
$9.02 M
|
$4.65 M
|
$2.61 M
|
$1.57 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$14.00 K
|
-$106.00 K
|
-$80.00 K
|
-$4.12 M
|
$68.00 K
|
$24.00 K
|
$0.00
|
| Operating Expenses |
$331.65 M
|
$219.83 M
|
$131.30 M
|
$83.69 M
|
$80.25 M
|
$52.81 M
|
$37.01 M
|
$27.68 M
|
$18.56 M
|
| Cost And Expenses |
$331.65 M
|
$221.02 M
|
$131.30 M
|
$83.69 M
|
$80.25 M
|
$52.81 M
|
$37.01 M
|
$27.68 M
|
$18.81 M
|
| Interest Income |
$10.94 M
|
$11.92 M
|
$16.11 M
|
$5.22 M
|
$10.82 M
|
$5.72 M
|
$0.00
|
$0.00
|
$759.00 K
|
| Interest Expense |
$13.49 M
|
$31.84 M
|
$16.11 M
|
$5.22 M
|
$10.82 M
|
$5.72 M
|
$1.48 M
|
$2.13 M
|
$0.00
|
| Depreciation & Amortization |
$2.29 M
|
$1.19 M
|
$1.23 M
|
$2.69 M
|
$2.39 M
|
$2.52 M
|
$676.00 K
|
$399.00 K
|
$253.00 K
|
| EBITDA |
$1.70 B |
-$206.69 M |
-$125.82 M |
-$76.56 M |
-$67.44 M |
-$42.60 M |
-$28.77 M |
-$19.31 M |
-$11.89 M |
| EBITDA Ratio |
8516.75
|
-114.83
|
-57.77
|
-10.75
|
-5.27
|
-4.69
|
-3.84
|
-2.43
|
-1.78
|
| Operating Income Ratio |
-1657.24
|
-121.79
|
-59.28
|
-10.75
|
-5.27
|
-4.81
|
-3.94
|
-2.48
|
-1.82
|
| Total Other Income/Expenses Net |
$2.02 B
|
-$20.50 M
|
-$29.90 M
|
-$5.20 M
|
-$8.19 M
|
-$6.79 M
|
-$1.41 M
|
-$2.10 M
|
-$739.00 K
|
| Income Before Tax |
$1.69 B
|
-$239.72 M
|
-$145.22 M
|
-$81.77 M
|
-$75.63 M
|
-$50.50 M
|
-$30.93 M
|
-$21.83 M
|
-$12.89 M
|
| Income Before Tax Ratio |
8437.87
|
-133.18
|
-66.68
|
-11.48
|
-5.91
|
-5.55
|
-4.12
|
-2.75
|
-1.93
|
| Income Tax Expense |
$2.00 K
|
$3.00 K
|
$3.00 K
|
$2.00 K
|
$3.00 K
|
$898.00 K
|
$96.00 K
|
$250.00 K
|
-$4.62 M
|
| Net Income |
$1.69 B
|
-$241.36 M
|
-$145.23 M
|
-$81.77 M
|
-$75.64 M
|
-$51.40 M
|
-$31.16 M
|
-$19.44 M
|
-$8.27 M
|
| Net Income Ratio |
8437.86
|
-134.09
|
-66.68
|
-11.48
|
-5.91
|
-5.65
|
-4.16
|
-2.45
|
-1.24
|
| EPS |
114.01 |
-5.12 |
-3.62 |
-2.15 |
-2.99 |
-1.41 |
-1.15 |
-0.68 |
-0.23 |
| EPS Diluted |
112.62 |
-5.12 |
-3.62 |
-2.15 |
-2.99 |
-1.41 |
-1.15 |
-0.68 |
-0.23 |
| Weighted Average Shares Out |
$14.48 M
|
$47.13 M
|
$40.11 M
|
$38.01 M
|
$25.26 M
|
$36.55 M
|
$27.08 M
|
$28.79 M
|
$36.55 M
|
| Weighted Average Shares Out Diluted |
$14.48 M
|
$47.13 M
|
$40.11 M
|
$38.01 M
|
$25.26 M
|
$36.55 M
|
$27.08 M
|
$28.79 M
|
$36.55 M
|
| Link |
|
|
|
|
|
|
|
|
|
